Day One Biopharmaceuticals
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | 49.6m | 131m | 268m |
| % growth | - | - | - | - | - | 165 % | 104 % |
| EBITDA | (13.7m) | (72.7m) | (147m) | (223m) | (284m) | (233m) | (80.4m) |
| % EBITDA margin | - | - | - | - | (572 %) | (177 %) | (30 %) |
| Profit | (40.5m) | (70.6m) | (142m) | (189m) | (158m) | (179m) | (82.1m) |
| % profit margin | - | - | - | - | (320 %) | (136 %) | (31 %) |
| EV / revenue | - | - | - | - | 21.5x | 8.9x | 4.1x |
| EV / EBITDA | - | -10.4x | -8.4x | -4.7x | -3.8x | -5.0x | -13.7x |
| R&D budget | 9.1m | 43.6m | 85.6m | 131m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | $60.0m | Series A | |
$130m | Series B | ||
| N/A | $160m | IPO | |
* | N/A | $173m | Post IPO Equity |
* | N/A | $150m | Post IPO Equity |
* | $175m | Private Placement VC | |
| Total Funding | AUD564m | ||
Related Content
Recent News about Day One Biopharmaceuticals
EditDay One Biopharmaceuticals focuses on developing innovative treatments for pediatric cancer through a collaborative approach involving multiple stakeholders. The company operates in the biopharmaceutical industry, targeting unmet medical needs in pediatric oncology. Its business model revolves around drug development, clinical trials, and partnerships with healthcare providers and research institutions. Revenue is generated through the commercialization of successful drug candidates and strategic alliances. Day One Biopharmaceuticals serves patients, healthcare providers, and research communities, aiming to improve outcomes for children with cancer.
Keywords: Pediatric cancer, drug development, clinical trials, biopharmaceuticals, oncology, collaborative research, healthcare partnerships, unmet medical needs, commercialization, strategic alliances.